Clinical trial

A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients

NCT00871780

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention BG00002 (natalizumab) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2009-08-01

PhasePHASE4

Conditions

Relapsing Remitting Multiple Sclerosis (RRMS)unresolved

Interventions

BG00002 (natalizumab)DRUG

Sponsors & collaborators

Biogenlead sponsor

Elan Pharmaceuticalscollaborator

Mapped research locations

WarsawPoland1 BucharestRomania1 PoznanPoland1 LodzPoland1 BialystokPoland1 LiègeBelgium1 KyivUkraine1 BydgoszczPoland1 KharkivUkraine1 LvivUkraine1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00871780 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.